Randomized Trial of Adjuvant Tamoxifen and/or Goserelin in Premenopausal Breast Cancer-Self-rated Physiological Effects and Symptoms

References

• Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet 1996; 348: 1189–96.
   Google Scholar
• Kaufman M, Minckwitz G. New Hormones. In: Bonnadonna G, Hortobagyi G, Gianni A, (eds.). Textbook of breast cancer. London: Martin Dunetz Ltd, 1997: 297–304.
   Google Scholar
• Bajetta E, Zilembo N, Buzzoni R, et al. Goserelin in pre-menopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 1994; 51: 262–9.
   PubMedGoogle Scholar
• Boccardo F, Rubagotti A, Perotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-peri-menopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994; 5: 337–42.
   PubMed Web of Science ®Google Scholar
• Jonat W. Luteinising hormone-releasing hormone ana-logues—the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 1998; 78: 5–8.
   PubMedGoogle Scholar
• Rutqvist LE. Zoladex® and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Can-cer Research Campaign (CRC.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.0). Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta 1999. Abstract # 251.
   Google Scholar
• Davidson N, O'Neill A, Vukov A, et al. Effect of chemohor-monal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta 1999. Abstract # 249.
   Google Scholar
• Jakesz R, Hausmaninger H, Samonigg H, et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast can-cer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncol-ogy (ASCO), Atlanta 1999. Abstract # 250.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamox-ifen for early breast cancer; an overview of the randomized trials. Lancet 1998; 351: 1451–67.
   Google Scholar
• Pomander T, Rutqvist LE, Willing N, Carlström K, von Schoultz B. Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 1993; 29A: 497–500.
   PubMedGoogle Scholar
• Rutqvist LE, Mattson A for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-staged breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398–406.
   Google Scholar
• Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996; 19: 308–19.
   PubMed Web of Science ®Google Scholar
• FenIon D. Menopause: a problem for breast cancer patients. Eur J Cancer Care 1995; 4: 166–72.
   PubMedGoogle Scholar
• Knobf MT. Natural menopause and ovarian toxicity associ-ated with breast cancer therapy. Oncol Nurs Forum 1998; 25: 1519–30.
   PubMedGoogle Scholar
• Feldman B, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985; 8: 261–8.
   Google Scholar
• Collins A, Landegren B-M. Reproductive health, use of estro-gen and experience of symptoms in perimenopausal women: a population-based study. Maturitas 1995; 20: 101–11.
   Google Scholar
• Hunter M. Predictors of menopausal symptoms: psychosocial aspects. In: Baillieres Clin Endocrinol Metab. London: Bail-liére Tindall, 1993: 33–45.
   Google Scholar
• Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. Re-view article. J Clin Oncol 1995; 13: 513–29.
   PubMed Web of Science ®Google Scholar
• Ficher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with node-negative lymph nodes and estrogen receptor-positive tumours. J Natl Cancer Inst 1996; 88: 1529–42.
   PubMedGoogle Scholar
• Canney PA, Hatton MQ. The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 1994; 6: 297–9.
   Google Scholar
• Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16: 501–14.
   Google Scholar
• Powles TJ, Jones AL, O'Brien MER, et al. The Royal Mars-den Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994; 31: 73–82.
   Google Scholar
• Jonat W, Kaufman M, Blarney RW, et al. A randomized study to compare the effect of luteinising hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 1994; 31A: 137–42.
   Google Scholar
• Berner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805.
   PubMedGoogle Scholar
• Hunt S, McKenna SP, McEwen J. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15A: 221–9.
   Google Scholar
• Schipper H, Clinch J, McMurray A. Measuring the quality of life of cancer patients: the Functional Living Index-cancer: development and validation. J Clin Oncol 1984; 2: 472–83.
   Google Scholar
• Heinrich RL, Schag CC, Ganz PA. Living with cancer: the cancer inventory of problem situations. J Clin Psychol 1984; 40: 972–80.
   Google Scholar
• Berglund G, Bolund C, Fornander T, Rutqvist LE, Sjöden PO. Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 1991; 27: 1075–81.
   Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70.
   PubMed Web of Science ®Google Scholar
• Herrmann C. International experiences with the hospital anx-iety and depression scale-a review of validation data and clinical results. J Psychosom Res 1996; 42: 17–41.
   Web of Science ®Google Scholar
• Sullivan M, Karlsson J, Sj6str6m L. Swedish obese subjects (SOS)-an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int J Obes Relat Metab Disord 1993; 17: 503–12.
   Google Scholar
• Brandberg Y, Bolund C, Sigurdardottir V, Sjöden PO, Sulli-van M. Anxiety and depressive symptoms at different stages of malignant melanoma. Psychooncology 1992; 1: 71–8.
   Google Scholar
• Statview. Berkeley, CA: Abacus Concepts, Inc, 1995.
   Google Scholar
• Fayers PM, Hand DJ. Factor analysis, causal indicators and quality of life. Qual Life Res 1997; 6: 139–50.
   PubMed Web of Science ®Google Scholar
• Polit D, Hungler B. Nursing research: principles and meth-ods. Philadelphia: Lippincott, 1995: 416–9.
   Google Scholar
• Morris J, Coyle D. Quality of life questionnaires in cancer clinical trials: imputing missing values. Psychooncology 1994; 3: 215–22.
   Web of Science ®Google Scholar
• Neymark N, Kiebert W, Toffs K, et al. Special paper. Metho-logical and statistical issues of quality of life and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer 1998; 9: 1317–33.
   Google Scholar
• Sprangers M, Cull A, Bjordal A, Groenvold M, Aaronsson NK. The European organization for research and treatment of cancer approach to quality of life assessment: guidelines for developing questionnaire modules. Qual Life Res 1993; 2: 287–95.
   Google Scholar